Jagsonpal to acquire 85% stake in Aequitas Healthcare for Rs 20.8 Cr
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts more than Nifty Microcap 250 and 3.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jagsonpal Pharmaceuticals will acquire 85% stake in Aequitas Healthcare for Rs 20.8 crore in cash, funded from internal accruals. Aequitas is a Mumbai-based pharma firm focused on hospital sales, with FY26 revenue of Rs 53.31 crore. The deal gives Jagsonpal entry into the hospital channel and institutional doctor network. Not a related party transaction. Expected to close by July 15, 2026.
Strategic entry into hospital channel. Rs 20.8 Cr cash deal funded internally, no debt impact. Aequitas adds about Rs 53 Cr annual revenue.